Integrating in vitro and in vivo data with algorithm-driven PK/PD modeling: a fast and efficient tool for evaluating cancer therapies in preclinical models

Session: PO.TB04.05 - 3D Models and Bioprinting       Board number: 6       Abstract number: 1222      

Session details: April 28, 2025, 9:00 AM - 12:00 PM, Section 1

Authors: Karina Adamowicz, David Cebrian, Fabio Dell' Aquila, Leanne Doyle, Agnieszka Drzał, Simone Esposito, Bartosz Płóciennik, Katarzyna Urbańska, Martyna Śniegocka

Add to your itinerary: https://www.abstractsonline.com/pp8/#!/20273/presentation/1174

This poster presents an integrated approach that combines in vitro and in vivo data to generate in silico PK/PD models of anti-cancer compounds. Validated with standard chemotherapies, the model streamlines preclinical studies by optimizing dose selection, reducing time and resource demands, and enabling efficient evaluation of drug candidates with minimal prior in vivo data. 

Development of an integrated multi-modal platform for comprehensive analysis of targeted protein degraders in a drug discovery setting

Session: PO.ET09.04 - Degraders and Glues 1       Board number: 26       Abstract number: 407       

Session details: April 27, 2025, 2:00 PM - 5:00 PM, Section 18

Authors: Magdalena Kiełtyka, Maciej Olszewski, Marta Smejda, Kamila Zaremba, Katarzyna Nosek, Magdalena Malik, Katarzyna Szafran

Add to your itinerary: https://www.abstractsonline.com/pp8/#!/20273/presentation/7283 

This poster presents our high-throughput analytical platform designed to optimize protein degrader candidates by integrating multiple orthogonal technologies. It highlights key analytical approaches, including binding assessments, ternary complex formation analysis, cellular degradation profiling, and proteome-wide specificity studies, demonstrating their role in accelerating targeted protein degradation (TPD) drug discovery. 

Subcutaneous tumor volume measurements: The method matters

Session: PO.TB02.02 - Imaging in Animal Models       Board number: 5       Abstract number: 58      

Session details: April 27, 2025, 2:00 PM - 5:00 PM, Section 3

Authors: Katarzyna Urbańska, Irmina Przydatek, Agnieszka Drzał, Karina Adamowicz, Fabio Dell'Aquila, Magdalena Chwalisz, Miłosz Gawenda, Martyna Śniegocka

Add to your itinerary: https://www.abstractsonline.com/pp8/#!/20273/presentation/1345

This poster compares three tumor volume measurement methods—caliper, TumorImager®, and Ultrasound Imaging—to assess their accuracy and correlation in preclinical cancer research. The findings highlight that caliper and ultrasound measurements are largely consistent, although ultrasounds measurements are much more precise and time consuming. TumorImager® results deviate due to its inability to capture tumor depth especially in small tumors. This emphasizes the need for method selection based on research objectives and tumor characteristics. 

High-content screening platform for comprehensive profiling in drug discovery

Session: PO.ET02.10 - Novel Methods in Small Molecule and Biologics Drug Discovery       Board number: 8       Abstract number: 5663      

Session details: April 29, 2025, 2:00 PM - 5:00 PM, Section 22

Authors: Maciej B. Olszewski, Natalia Gostynska, Klaudia Lesniak, Alicja Martyniak, Magdalena Kiełtyka

Add to your itinerary: https://www.abstractsonline.com/pp8/#!/20273/presentation/3731

This poster presents our high-content screening (HCS) platform designed for fast and quantitative assessment of cellular phenotypes across diverse research applications. By integrating advanced fluorescence microscopy, automated analysis, and machine learning it enables multiparametric assessment of morphological, functional, and molecular properties. The platform supports a range of kinetic and endpoint assays, including viability, apoptosis, and proliferation studies. This system facilitates therapeutic target validation, mechanism of action studies, pharmacological screening, and toxicity assessment with high reproducibility and adaptability.

Contact us